Corbus Pharma (NASDAQ:CRBP) Rating Maintained
Cantor Fitzgerald currently has a $28.0 price target on the $365.26 million market cap company or 294.37 % upside potential. In analysts report issued to investors and clients on Thursday, 14 December, Corbus Pharma (NASDAQ:CRBP) stock had its Overweight Rating reaffirmed by professional analysts at Cantor Fitzgerald.
NASDAQ:CRBP is currently trading -3.23% lower at $7.50 as of 8:15 AM New York time. Corbus Pharma’s stock is 0% over the past 200 days. It has underperformed the Standard & Poor’s 500 index, which has added 6.00% over the same time period.
Corbus Pharma (NASDAQ:CRBP) Profile
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Corbus Pharma (NASDAQ:CRBP) traded down -3.23% on 14 December, hitting $7.5. A total of 1.32 million shares of the company’s stock traded hands. This is down from average of 1.54 million shares. Corbus Pharma has a 52 week low of $1.91 and a 52 week high of $10.78. The company has a market cap of $365.26 million and a P/E ratio of 0.
Get the latest Corbus Pharma (NASDAQ:CRBP) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Analysts at Cantor Fitzgerald Maintain their Overweight rating for Corbus Pharma (NASDAQ:CRBP) with $28.0 Price Objective appeared first on Octafinance.